New Hope for Esophageal Squamous Cell Carcinoma Treatment as Deferasirox Targets TAOK1 to Induce p53 Mediated Apoptosis
Nikhil Prasad Fact checked by:Thailand Medical News Team Feb 13, 2025 1 month, 2 days, 17 hours, 55 minutes ago
Medical News: Chinese Scientists Unveil a Potential New Treatment for Esophageal Squamous Cell Carcinoma
Researchers from Zhengzhou University in China have made a breakthrough in the treatment of esophageal squamous cell carcinoma (ESCC), a highly aggressive form of esophageal cancer. Their study highlights the potential of Deferasirox (DFO), an iron-chelating drug, in targeting a crucial protein called TAOK1. By inhibiting this protein, the drug induces p53-mediated apoptosis, leading to cancer cell death. The discovery could open doors to new therapeutic strategies for patients suffering from ESCC, a disease with limited treatment options and a low survival rate.
New Hope for Esophageal Squamous Cell Carcinoma Treatment as Deferasirox Targets TAOK1 to Induce p53 Mediated Apoptosis
How Deferasirox Works Against Cancer Cells
ESCC is a devastating disease due to its rapid progression and late-stage diagnosis. Current treatment options include surgery, chemotherapy, and radiation therapy, but these approaches often have limited effectiveness. This
Medical News report highlights how researchers sought to explore new avenues for treatment by investigating the role of TAOK1, a kinase protein involved in tumor growth.
The study found that Deferasirox, a drug commonly used to treat iron overload conditions, significantly inhibits ESCC cell proliferation by directly targeting TAOK1. This protein has been previously linked to several cancers, but its role in ESCC was not fully understood. Researchers conducted in vitro and in vivo experiments and confirmed that blocking TAOK1 leads to enhanced activation of p53, a tumor suppressor protein. The activation of p53 triggers apoptosis, a natural process that eliminates damaged or cancerous cells.
Key Findings from the Study
One of the most important findings of the research was that Deferasirox was able to suppress cancer cell growth at relatively low concentrations, demonstrating its potential as a targeted therapy. The researchers performed experiments on human ESCC cell lines and found that Deferasirox inhibited their proliferation in a dose-dependent manner.
Further analysis showed that Deferasirox binds directly to TAOK1 and reduces its kinase activity. The suppression of TAOK1 resulted in increased expression of apoptosis-related proteins such as Puma, Noxa, and Bax, while anti-apoptotic proteins like Bcl-2 were significantly decreased. This shift in protein expression patterns confirmed that Deferasirox effectively promotes cancer cell death through the p53-mediated apoptosis pathway.
In Vivo Experiments Confirm the Effectiveness of Deferasirox
To further validate their findings, researchers conducted in vivo studies using patient-derived xenograft (PDX) mouse models. The results were highly promising - mice treated with Deferasirox showed a significant reduction in tumor volume compared to untreated control groups.
Histological and immunohistochemical analyses revealed that Deferasirox-treated tumors had reduced levels of TAOK1 and
Ki-67, a marker associated with cell proliferation. At the same time, p53 expression was markedly increased, reinforcing the drug’s ability to induce cancer cell apoptosis. Importantly, the treatment did not cause any observable toxicity in the mice, indicating that Deferasirox could be a safe therapeutic option.
Potential Implications for Cancer Treatment
The study’s findings suggest that Deferasirox could be repurposed as a targeted therapy for ESCC. Unlike conventional chemotherapy, which can affect both healthy and cancerous cells, Deferasirox specifically targets TAOK1, making it a potentially more effective and less toxic treatment option.
This research is particularly exciting because it highlights an alternative mechanism of Deferasirox beyond its traditional role in iron chelation. While previous studies have suggested that iron chelators may have anti-cancer properties, this study demonstrates that Deferasirox can work independently of its iron-removing function by directly inhibiting TAOK1. This insight paves the way for further investigations into the use of iron-chelating drugs in oncology.
Conclusion
The discovery that Deferasirox can effectively inhibit ESCC growth by targeting TAOK1 and activating p53-mediated apoptosis marks a significant advancement in cancer research. The drug's ability to suppress tumor growth both in laboratory and animal models suggests that it holds promise as a novel treatment for ESCC. Future clinical trials will be necessary to determine its effectiveness in human patients. If successful, Deferasirox could become an important addition to the limited arsenal of therapies available for ESCC, offering new hope to patients battling this aggressive cancer.
The study findings were published in the peer-reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/26/4/1524
For the latest Cancer News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/micrornas-and-their-role-in-esophageal-cancer
https://www.thailandmedical.news/news/thailand-medical-study-finds-combined-chemotherapy-and-radiation-boost-survival-in-advanced-esophageal-cancer
https://www.thailandmedical.news/news/uk-study-finds-that-erectile-dysfunction-drugs-which-are-basically-pde5-inhibitors-are-effective-to-treat-certain-cancers-including-esophageal-tumors
https://www.thailandmedical.news/news/doctors-warn-that-covid-19-can-cause-spontaneous-esophageal-rupture
https://www.thailandmedical.news/articles/cancer
Follow us on:
https://x.com/ThailandMedicaX
https://www.facebook.com/ThailandMedicalNews
https://bsky.app/profile/thailandmedical.bsky.social
https://gettr.com/user/thailandmedicalnews
https://www.tribel.com/thailandmedical/wall
and 33 other social media platforms
Share
Tweet
Share
